**ELIFE SCIENCE** 



## Oligosaccharide Replacement of a Therapeutic Antibody by using Endo-M and Glycosynthase

## As a result of chemoenzymatic glycoengineering, multi-form *N*-linked oligosaccharides of a therapeutic antibody were replaced by the structure fine-defined oligosaccharide

In recent years, the expectation of a therapeutic benefit for antibody drugs is growing and the development of industrial technology for antibody production is required. However, heterogeneity of glycosylation of antibody drugs has long been left unsolved. In this context, TCI achieved introduction of a MONO-form oligosaccharide to a therapeutic antibody by using our enzyme products, "Endo-M" and "Glycosynthase".



Please harness TCI's [Endo-M], [Glycosynthase] and [Chemically Synthesized Oligosaccharides] for the benefit of your Research & Development.

## **Oligosaccharide Replacement of a Therapeutic Antibody** by using Endo-M and Glycosynthase

Cleavage of multi-form oligosaccharides by Endo-M and coupling of MONO-form oligosaccharide by Glycosynthase were conducted under non-reducing condition. Verification of enzymatic reaction was performed with capillary electrophoresis (Fig. 1) and SDS-PAGE (Fig. 2A). The terminal sialic acid of the chemoenzymatically-transferred N-linked oligosaccharide to the therapeutic antibody was detected by lectin blotting using a sialic acid binding lectin (Fig. 2B).



• Chemicals itemized in this brochure are for research and testing use only. Please avoid use other than by chemically knowledgeable professionals. • Information such as listed products and its specifications and so on are subject to change without prior notice. • The contents may not be reproduced or duplicated in whole or in part without permission of Tokyo Chemical Industry Co., Ltd.

Tel

Fax

E-mail